In the News

Arzeda Uses Synthetic DNA for Sustainable Industrial Chemicals

  • April 21, 2016

Biological solutions provider Arzeda said on Wednesday that it has entered into an agreement with gene synthesis company Gen9 to purchase mass quantities of synthetic DNA for development of sustainable industrial chemicals.

Under the agreement Gen9 will supply megabase quantities of synthetic DNA that will enable Arzeda to accelerate development of novel molecules for its own products as well as those of its partners.

Arzeda plans to use Gen9 synthetic DNA as part of its program to create a portfolio of enzymes and specialty chemicals for polymers, novel crop traits, pharmaceuticals, industrial chemicals and other advanced materials.

READ MORE

CO2 Can Be Part of the Solution

  • April 20, 2016

Arzeda is an additional company that utilizes sunlight and CO2 to produce chemicals and nutrient-enhanced animal feed. The company today announced a partnership with Cambridge, Massachusetts-based gene synthesis company Gen9. Arzeda will use Gen9’s synthetic biology platform to develop novel crop traits and enzymes. Arzeda on Tuesday gave a presentation on how its enzymes enable animal producers to make more use of silage and forage feeds by increasing their nutritive value.

READ MORE

DNA Synthesis Steps Up -  GEN

  • April 15, 2016

While the next-generation approach of the BioFab platform enables tremendous scale to meet the growing need for synthetic DNA, continual innovation is necessary on the journey toward realizing Moore’s Law for gene synthesis. To further scale the BioFab platform, Gen9 recently applied multiplexing technology to long-length DNA construction by building 50 gene-length constructs simultaneously in a single reaction.

READ MORE

Tools and Trends: Forecasts in SynBio from Industry Leaders

  • March 30, 2016

Three cents per base pair for industrial use of synthetic DNA. That’s the big breakthrough that Gen9 recently announced, further redefining the economics of the synbio industry. Rather than paying 25 cents per base pair generated by old-fashioned gene synthesis, Gen9 partners will pay about one-eighth that amount. Gen9’s new offering enables scientists to catalyze their research by testing thousands of protein variants, building multiple versions of complex pathways and reducing the overall time to discovery.

READ MORE

Gen9 Announces Lower-Cost DNA Synthesis, Seeks Partners for Access Program

  • March 28, 2016

NEW YORK (GenomeWeb) – DNA synthesis firm Gen9 is looking test drive the newest generation of its BioFab platform, and to do so it needs lots of researchers who themselves need lots of DNA constructs.

"Underline lots," Gen9 VP of R&D and Operations Devin Leake told GenomeWeb. BioFab is designed to operate at high throughput, which allows the company to offer DNA at a lower per-base price than ever before. 

READ MORE

Gen9, SynbiCITE Partner on Access to Gene Synthesis for Synthetic Biology – GenomeWeb

  • February 17, 2016

NEW YORK (GenomeWeb) – DNA construction firm Gen9 and British synthetic biology network SynbiCite have announced a partnership to increase access to gene synthesis technology. Under the terms of the agreement, SynbiCite members will have access to Gen9's BioFab high-throughput gene synthesis platform.

READ MORE

Gen9 Announces New Multiplex Synthesis Platform for Rapid Assembly of Gene-length DNA – SynBioBeta

  • February 9, 2016

With applications in pharmaceutical, chemical, and fuel companies, synthetic biology is a rapidly-growing area of scientific development working at the cutting edge of knowledge and innovation. Whether creating next-generation biofuels or industrial chemicals, synthetic biology relies on the design and construction of specifically designed genes and DNA fragments. The process of synthesizing DNA has developed rapidly over the last decade and now Gen9, a company dedicated to improving and enabling powerful synthetic biology techniques, has announced the next step in synthetic DNA synthesis.

READ MORE

Using synthetic bacterial enhancers to reveal a looping-based mechanism for quenching-like repression – Nature

  • February 5, 2016

Distal regulation by transcription factors, which are bound in cis, yet some distance away from the core promoters, is a regulatory phenomenon ubiquitous in all organisms. Mechanistically, DNA looping has been implicated in distal regulation in eukaryotes and has been shown directly to be involved in σ54 promoter expression in bacteria. However, most structural features of distal regulatory regions such as the importance of having several binding sites for a given transcription factor, the genomic distance of these binding sites from the basal promoter and the functional significance of particular arrangements of the binding sites remain poorly understood. 

READ MORE

Gene editing, plastic surgery and woolly mammoths: My 20 minutes with George Church – Boston Business Journal

  • January 29, 2016

While I’d known about Church for years in connection with startups such as Editas Medicine, EnEvolv, Warp Drive Bio and Gen9 Bio, the opportunity to interview him in person came about through his involvement in an upcoming panel discussion around the ethical questions involved in the relatively new science of gene editing and an underlying technology called CRISPR, a method of efficiently and precisely cutting DNA. The panel, to be moderated by Antonio Regalado, senior editor for biomedicine at MIT Technology Review, and hosted by MIT Enterprise Forum of Cambridge, is planned for Feb. 3 at the Broad Institute in Cambridge.

READ MORE

Reducing Repetition While Building Biopolymers – The Scientist

  • January 11, 2016

To test their algorithm, the researchers selected 19 repetitive proteins commonly used in materials science and biology, including the protein mussels use to adhere to surfaces, and artificial polypeptides inspired by silks and elastins. Chilkoti and Tang ran the amino acid sequences of their proteins through their algorithm. They then produced DNA sequences encoding each protein either in-house or by sending their sequences to the companies Gen9 or Genscript. The researchers found that they were able to harness E. coli to produce proteins using all of the DNA sequences they had produced.

READ MORE